HIVワクチン市場：フェーズ別、カテゴリー別、抗体別、エンドユーザー別-2025-2030年の世界予測

HIVワクチン市場は、2023年に8億3,508万米ドルと評価され、2024年には9億4,005万米ドルに達すると予測され、CAGR 12.88%で成長し、2030年には19億5,126万米ドルに達すると予測されています。

HIVワクチン市場の範囲と定義には、ヒト免疫不全ウイルス（HIV）感染予防を目的としたワクチンの開発、生産、流通が含まれます。HIVワクチンの必要性は、世界中で数百万人が罹患しているHIV/AIDSの絶え間ない世界的影響と、抗レトロウイルス療法や曝露前予防薬（PrEP）のような現在の予防手段の有効性が限られていることから生じる。主な用途は、ヘルスケア従事者、リスクの高い性行動をとる個人、HIVの蔓延が高い地域など、リスクのある集団での使用です。最終使用範囲には、これらのワクチンをより広範な公衆衛生戦略に組み込むことを目指す病院、研究機関、地域保健センターが含まれます。市場成長を促進する主な要因としては、研究開発への多額の投資、認知度の向上、政府による奨励、バイオテクノロジーの進歩が挙げられ、これによってバイオテクノロジー会社は臨床試験を進めるために公衆衛生機関と提携するようになります。潜在的なビジネスチャンスは、より効果的なワクチン候補を創出するために遺伝子工学や合成生物学を活用する、既存の製薬企業と革新的なバイオテクノロジー企業とのコラボレーションの拡大にあります。こうした機会を捉えるための提言としては、戦略的提携の強化や、画期的な臨床試験に向けた資金提供の増加が挙げられます。しかし、市場成長の妨げとなっているのは、研究開発費の高騰、規制当局の複雑な承認プロセス、治験集団における倫理的配慮、さらに、特に資源が限られた環境におけるワクチンの流通と投与の確保における物流の課題です。これらを克服するため、企業は、他のウイルス感染症で有効性を示したmRNAワクチン技術や、多様な集団の遺伝子マーカーに合わせた個別化ワクチンなどの革新的分野に注力しなければならないです。市場に関する考察では、技術革新の緊急性によって競争は激化しているもの、世界ヘルスの目標を共有することによって育まれる協力的なエコシステムによってバランスが保たれていることが示唆されています。持続可能な実践と公平なアクセスを優先することで、ビジネスの成長だけでなく、世界規模での健康への変革的影響も約束されます。

市場力学：急速に進化するHIVワクチン市場の主要市場インサイトを公開

HIVワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のエイズに対する意識の高まりと効果的な治療薬の必要性
  • HIV治療薬に対する政府の支援体制と政策
  • HIV蔓延に対する政府およびNGOの啓発キャンペーンの増加
• 市場抑制要因
  • HIVワクチンの商業化と標準化に関連する厳しい規制
• 市場機会
  • CRISPR遺伝子編集とAIによるHIV予測モデリングにおける技術革新
  • 政府機関とバイオテクノロジー企業間の研究開発パートナーシップの増加
• 市場の課題
  • 製剤化に伴う複雑さと製品回収事例

ポーターのファイブフォース：HIVワクチン市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：HIVワクチン市場における外部からの影響の把握

外部マクロ環境要因は、HIVワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析HIVワクチン市場における競合情勢の把握

HIVワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスHIVワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、HIVワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨HIVワクチン市場における成功への道筋を描く

HIVワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • エイズに関する意識が世界中で高まり、効果的な治療薬の必要性が高まっている
    • HIV治療薬に対する政府の支援的枠組みと政策
    • HIV流行の啓発のための政府およびNGOによるキャンペーンの増加
  • 抑制要因
    • HIVワクチンの商業化と標準化に伴う厳しい規制
  • 機会
    • CRISPR遺伝子編集とAI駆動型HIV予測モデリングにおける技術革新
    • 政府機関とバイオテクノロジー企業間の研究開発パートナーシップの増加
  • 課題
    • 医薬品の処方に関する複雑さと製品リコールの事例
• 市場セグメンテーション分析
  • フェーズ：公衆衛生を確保するために、いくつかのフェーズを通じてHIVワクチンを厳密にテストします
  • エンドユーザー：HIVの流行を抑制し、撲滅するために、公共ヘルスケア施設でHIVワクチンを広く使用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 HIVワクチン市場フェーズ別

• フェーズI
• フェーズII
• フェーズIII

第7章 HIVワクチン市場：カテゴリ別

• 予防ワクチン
• 治療ワクチン

第8章 HIVワクチン市場抗体別

• 10E8
• 広域中和抗体
• PG9とPG16
• ＶＲＣ０１

第9章 HIVワクチン市場：エンドユーザー別

• 臨床研究センター
• 病院
• 公的ヘルスケア機関

第10章 南北アメリカのHIVワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のHIVワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのHIVワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Uvax Bio、オーストラリアでの臨床試験でHIVワクチン開発を前進
  • FDA、新型HIVワクチンHB-500ワクチンのヒト試験を承認
  • アブサイとカリフォルニア工科大学の革新的な協力で、手頃な価格のHIV治療ワクチンを開発
• 戦略分析と提言

企業一覧

• AlphaVax, Inc.
• Antigen Express, Inc. by Generex Biotechnology Corporation
• Argos Therapeutics, Inc.
• Bavarian Nordic
• Bionor Holding AS
• Celldex Therapeutics, Inc.
• GeneCure LLC
• Genetic Immunity, Inc.
• GenVec, Inc.
• GeoVax Labs, Inc.
• GlaxoSmithKline PLC
• Immune Response BioPharma, Inc.
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson
• Moderna Inc.
• Novartis AG
• Oncolys BioPharma Inc.
• Sanofi S.A.
• TVAX Biomedical, Inc.

LIST OF FIGURES

• FIGURE 1. HIV VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. HIV VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HIV VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HIV VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HIV VACCINES MARKET SIZE, BY 10E8, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY BROADLY NEUTRALIZING ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HIV VACCINES MARKET SIZE, BY PG9 AND PG16, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HIV VACCINES MARKET SIZE, BY VRC01, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICAL RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 36. CANADA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 38. CANADA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 39. CANADA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 58. CHINA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 60. CHINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 61. CHINA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 62. INDIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 64. INDIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 65. INDIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 131. ITALY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 133. ITALY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 134. ITALY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 147. POLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 149. POLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 150. POLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 151. QATAR HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 153. QATAR HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 154. QATAR HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 191. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

The HIV Vaccines Market was valued at USD 835.08 million in 2023, expected to reach USD 940.05 million in 2024, and is projected to grow at a CAGR of 12.88%, to USD 1,951.26 million by 2030.

The scope and definition of the HIV vaccines market encompass the development, production, and distribution of vaccines aimed at preventing Human Immunodeficiency Virus (HIV) infections. The necessity for HIV vaccines arises from the continuous global impact of HIV/AIDS, with millions affected worldwide, and the limited effectiveness of current preventive measures like antiretroviral therapies and pre-exposure prophylaxis (PrEP). The primary applications involve their use in at-risk populations, including healthcare workers, individuals with high-risk sexual behavior, and regions with high HIV prevalence. End-use scopes include hospitals, research institutes, and community health centers aiming to integrate these vaccines into broader public health strategies. Key factors driving market growth include substantial investments in R&D, rising awareness, and government incentivization, alongside advancements in biotechnology, which foster biotechnology companies to partner with public health organizations to advance clinical trials. Potential opportunities lie in the growing collaborations between established pharmaceutical firms and innovative biotechs, leveraging genetic engineering and synthetic biology to create more effective vaccine candidates. Recommendations to seize these opportunities include enhancing strategic alliances and increasing funding towards groundbreaking clinical trials. However, market growth is hampered by high R&D costs, complex regulatory approval processes, and ethical considerations in trial populations, as well as logistical challenges in ensuring vaccine distribution and administration, especially in resource-limited settings. To overcome these, businesses must focus on areas of innovation such as mRNA vaccine technologies, which have shown efficacy in other viral infections, and personalized vaccines tailored to genetic markers of diverse populations. Insights into the market suggest a competitive nature intensified by the urgency to innovate, yet balanced by the collaborative ecosystem fostered by shared global health objectives. Prioritizing sustainable practices and equitable access promises not only business growth but also transformative health impacts on a global scale.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HIV Vaccines Market

The HIV Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing awareness about AIDS worldwide and the need for effective medications
  • Supportive government frameworks and policies for HIV drugs
  • Increasing number of government and NGO campaigns for awareness of the HIV epidemic
• Market Restraints
  • Strict regulations associated with the commercialization and standardization of HIV vaccines
• Market Opportunities
  • Technological innovations in CRISPR gene-editing and AI-driven predictive modeling for HIV
  • Increasing number of R&D partnerships between government bodies and biotechnology firms
• Market Challenges
  • Complexities associated with drug formulation and cases of product recalls

Porter's Five Forces: A Strategic Tool for Navigating the HIV Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HIV Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HIV Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HIV Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HIV Vaccines Market

A detailed market share analysis in the HIV Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HIV Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HIV Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the HIV Vaccines Market

A strategic analysis of the HIV Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the HIV Vaccines Market, highlighting leading vendors and their innovative profiles. These include AlphaVax, Inc., Antigen Express, Inc. by Generex Biotechnology Corporation, Argos Therapeutics, Inc., Bavarian Nordic, Bionor Holding AS, Celldex Therapeutics, Inc., GeneCure LLC, Genetic Immunity, Inc., GenVec, Inc., GeoVax Labs, Inc., GlaxoSmithKline PLC, Immune Response BioPharma, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Moderna Inc., Novartis AG, Oncolys BioPharma Inc., Sanofi S.A., and TVAX Biomedical, Inc..

Market Segmentation & Coverage

This research report categorizes the HIV Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Phase, market is studied across Phase I, Phase II, and Phase III.
• Based on Category, market is studied across Preventive Vaccines and Therapeutic Vaccines.
• Based on Antibodies, market is studied across 10E8, Broadly Neutralizing Antibodies, PG9 and PG16, and VRC01.
• Based on End Users, market is studied across Clinical Research Centers, Hospitals, and Public Healthcare Providers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing awareness about AIDS worldwide and the need for effective medications
    • 5.1.1.2. Supportive government frameworks and policies for HIV drugs
    • 5.1.1.3. Increasing number of government and NGO campaigns for awareness of the HIV epidemic
  • 5.1.2. Restraints
    • 5.1.2.1. Strict regulations associated with the commercialization and standardization of HIV vaccines
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological innovations in CRISPR gene-editing and AI-driven predictive modeling for HIV
    • 5.1.3.2. Increasing number of R&D partnerships between government bodies and biotechnology firms
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities associated with drug formulation and cases of product recalls
• 5.2. Market Segmentation Analysis
  • 5.2.1. Phase: Rigorous testing of HIV vaccines through several phases to ensure public health
  • 5.2.2. End Users: Extensive usage of HIV vaccines in public healthcare facilities to control and combat the HIV epidemic
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. HIV Vaccines Market, by Phase

• 6.1. Introduction
• 6.2. Phase I
• 6.3. Phase II
• 6.4. Phase III

7. HIV Vaccines Market, by Category

• 7.1. Introduction
• 7.2. Preventive Vaccines
• 7.3. Therapeutic Vaccines

8. HIV Vaccines Market, by Antibodies

• 8.1. Introduction
• 8.2. 10E8
• 8.3. Broadly Neutralizing Antibodies
• 8.4. PG9 and PG16
• 8.5. VRC01

9. HIV Vaccines Market, by End Users

• 9.1. Introduction
• 9.2. Clinical Research Centers
• 9.3. Hospitals
• 9.4. Public Healthcare Providers

10. Americas HIV Vaccines Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific HIV Vaccines Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa HIV Vaccines Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Uvax Bio Progresses HIV Vaccine Development with Australian Clinical Trial
  • 13.3.2. FDA Approves Novel HIV Vaccine, HB-500 Vaccine for Human Testing
  • 13.3.3. Innovative Collaboration Between Absci and Caltech to Develop Affordable HIV Therapeutic Vaccine
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AlphaVax, Inc.
• 2. Antigen Express, Inc. by Generex Biotechnology Corporation
• 3. Argos Therapeutics, Inc.
• 4. Bavarian Nordic
• 5. Bionor Holding AS
• 6. Celldex Therapeutics, Inc.
• 7. GeneCure LLC
• 8. Genetic Immunity, Inc.
• 9. GenVec, Inc.
• 10. GeoVax Labs, Inc.
• 11. GlaxoSmithKline PLC
• 12. Immune Response BioPharma, Inc.
• 13. Inovio Pharmaceuticals, Inc.
• 14. Johnson & Johnson
• 15. Moderna Inc.
• 16. Novartis AG
• 17. Oncolys BioPharma Inc.
• 18. Sanofi S.A.
• 19. TVAX Biomedical, Inc.